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Abstract
Background: Current technologies in next-generation sequencing are offering high throughput reads at low costs,
but still suffer from various sequencing errors. Although pyro- and ion semiconductor sequencing both have the
advantage of delivering long and high quality reads, problems might occur when sequencing homopolymer-
containing regions, since the repeating identical bases are going to incorporate during the same synthesis cycle,
which leads to uncertainty in base calling. The aim of this study was to evaluate the analytical performance of a
pyrosequencing-based next-generation sequencing system in detecting homopolymer sequences using
homopolymer-preintegrated plasmid constructs and human DNA samples originating from patients with cystic
fibrosis.
Results: In the plasmid system average correct genotyping was 95.8% in 4-mers, 87.4% in 5-mers and 72.1% in
6-mers. Despite the experienced low genotyping accuracy in 5- and 6-mers, it was possible to generate amplicons
with more than a 90% adequate detection rate in every homopolymer tract. When homopolymers in the CFTR
gene were sequenced average accuracy was 89.3%, but varied in a wide range (52.2 – 99.1%). In all but one case,
an optimal amplicon-sequencing primer combination could be identified. In that single case (7A tract in exon
14 (c.2046_2052)), none of the tested primer sets produced the required analytical performance.
Conclusions: Our results show that pyrosequencing is the most reliable in case of 4-mers and as homopolymer
length gradually increases, accuracy deteriorates. With careful primer selection, the NGS system was able to correctly
genotype all but one of the homopolymers in the CFTR gene. In conclusion, we configured a plasmid test system that
can be used to assess genotyping accuracy of NGS devices and developed an accurate NGS assay for the molecular
diagnosis of CF using self-designed primers for amplification and sequencing.
Keywords: Pyrosequencing, Homopolymer detection, Cystic fibrosis
* Correspondence: balogh@med.unideb.hu
1Department of Laboratory Medicine, University of Debrecen, Nagyerdei krt.
98, Debrecen H-4032, Hungary
4Division of Clinical Genetics, University of Debrecen, Nagyerdei krt. 98,
Debrecen H-4032, Hungary
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ivády et al. BMC Genomics  (2018) 19:158 
https://doi.org/10.1186/s12864-018-4544-x
Background
In genomics, a homopolymer (HP) is a sequence of con-
secutive identical bases. Approximately 1.43 million HPs
(also known as mononucleotide microsatellites) exist in
the human exome, with the size of 4-mer and up. This
also means that an average of eight such HP sequences
can be found in every exon. They are believed to play
roles in transcriptional regulation and recombination [1,
2], and the vast majority (96.7%) of them are in the
range of 4-mer to 6-mer. HP sequences composed of
A:T base pairs are over-represented in the human gen-
ome compared to G:C HPs [3–5]. Although both pairs
show structural stability [6, 7], these loci in the genome
are highly mutagenic and have been characterized as
hotspots for length change mutations [8–10], which has,
presumably, contributed to their reduced occurrence in
the exome over time.
Certain sequencing-by-synthesis based next generation
sequencing (NGS) techniques have a relatively high error
rate in determining homopolymer regions, due to the
principles used for detection. In pyrosequencing [11–13]
or ion semiconductor sequencing [14], the signal which
depends on the emitted light or the concentration of re-
leased hydrogen ions, respectively, should be directly pro-
portional to the number of incorporated bases during a
single dNTP dispensation. However, since linearity starts
to diminish in HP stretches exceeding four bases, errone-
ous over- and under calls are going to happen [15–17].
Since HPs are more prone to insertion and deletion muta-
tions (indels), problems are going to aggravate, when util-
izing pyrosequencers or ion semiconductor chemistry in
diagnostic procedures [18].
There are numerous bioinformatic correction tools to
separate artifacts from true genetic variations. Some of
these algorithms are based on clustering the flowgrams;
for example Denoiser, which utilizes rank-abundance
distributions, or PyroNoise/AmpliconNoise, which cal-
culates a likelihood using empirically derived error dis-
tributions [19]. Acacia’s main focus is on HP sequences
and the algorithm uses a dynamically updated cluster
consensus when aligning reads [20]. Coral and ECHO
are multiple alignment based techniques [21], while
HECTOR is a homopolymer spectrum based error cor-
rector, with a multistage correction workflow [22]. An-
other useful software is FlowClus, which provides
feedback on the denoising process, allowing the user to
apply more suitable analysis parameters for the particu-
lar dataset [23]. The most recent tools, such as NoDe
(Noise Detector) and DUDE-Seq are believed to produce
even lower error rates and are more time-efficient [24,
25]. Even if sophisticated correction tools [22, 26, 27]
are used to overcome the difficulties of detection and
significantly improve accuracy, it is still very important
to estimate the capability of the corresponding NGS
system to correctly determine HPs. To avoid uncertainty
in the diagnostic testing of patient samples, it is also rec-
ommended that the maximum length of stable HP de-
tection, for reasonable identification of indel mutations
in such sequences, be defined before using the NGS in-
strument in routine clinical practice [28].
The coding region of the cystic fibrosis transmembrane
regulator gene (CFTR) contains 24 homopolymer stretches,
involving 17 out of 27 exons. In conjunction with the
whole genome, T and A homopolymers vastly outnumber
G and C homopolymers; 14 thymine, 8 adenine, 2 guanine
and no cytosine HPs are present. In exon 14 there is a
seven adenine long homopolymer region (c.2046_2052)
and genetic alterations affecting this region could create
poly-A tracts of different sizes, e.g. the pathogenic muta-
tion c.2051_2052delAAinsG (2183delAAinsG) results in a
five, while c.2052delA (2184delA) results in a six adenine
long homopolymer segment. In case of the relatively fre-
quent c.2052_2053insA (2184insA) mutation an eight ad-
enine long homopolymer stretch is formed.
To assess the analytical validity of pyrosequencing-
based NGS technology and to test the optimization possi-
bilities, two experimental test systems were developed. In
the first, homopolymer sessions were introduced into
plasmid vectors and the resultant plasmids were used as
templates for subsequent sequencing experiments. Next
we analyzed the CFTR gene to also assess the analytical
performance of a newly developed pyrosequencing-based
assay on patient samples. In this second experiment, all
homopolymer-containing and non-HP CFTR exons were
tested. These samples originated from cystic fibrosis (CF)
patients with known CFTR mutation status. Assessment
of the Ion Torrent platform was carried out in a similar
way and the results were recently published [29].
Another reason for investigating the CFTR gene was
that the above mentioned CF producing mutation
(2184insA) is very common in certain geographical re-
gions of Europe [30], including Hungary [31, 32]. Des-
pite, current CF mutation detection kits do not cover
this particular mutation site.
Methods
The two assay systems, which were used during the ex-
periments are shown on Fig. 1. To test the analytical
performance of the Roche pyrosequencing-based bench-
top NGS system (Roche 454 Life Sciences, Branford, CT,
USA) in assessing homopolymer sequences, a series of
plasmid vectors were generated using pcDNA3.1 as a
template (Invitrogen, Life Technologies, Carlsbad, CA).
Altogether 12 clones were produced (4-mer, 5-mer, and
6-mer homopolymers of all four nucleotides) using site-
directed mutagenesis and following the manufacturer’s
instructions (Quikchange II, Agilent Technologies, Santa
Clara, CA). In order to avoid the possible generation of
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length-change mutations during the plasmid replication
and the amplification of the specific fragments, PicoMaxx
enzyme mix that contains Pfu DNA polymerase (Agilent
Technologies, Santa Clara, CA) was utilized. As a quality
control step, two colonies of the site-directed mutagenesis
were analyzed and confirmed by Sanger sequencing in
case of all mutations (Additional file 1: Figure S1).
Each homopolymer tract in the plasmid system was in-
vestigated using three pairs of primers (Fig. 1) in order
to test the hypothesis, that in the beginning of the se-
quencing reaction a sufficiently high signal-to-noise ratio
might enable precise HP length detection. Our primer
design was as follows: i) the homopolymer was located
in the vicinity of the forward amplification/sequencing
primer in 3′ direction, ii) the analyzed homopolymers
were located approximately in the middle of the ampli-
con and iii) the reverse amplification/sequencing
primer’s 3′ end was generated to be as close as possible
to the HP segment. Primers used for mutagenesis, amp-
lification, and sequencing are listed in Additional file 2:
Table S1. The size of the homopolymer clones varied be-
tween 366 and 387 bp, depending on the HP length and
the primers used.
In the second set of experiments, a CFTR gene muta-
tion detection system was developed and analyzed in de-
tail. 17 clinical samples were used with known CFTR
mutation status determined by an in vitro diagnostic
assay (Elucigene CF29v2, Elucigene Diagnostics, Man-
chester, UK) and Sanger sequencing. Representative elec-
tropherograms of the clinical samples are shown in
Additional file 3 Figure S2 and Additional file 4 Figure
S3 (all HP-containing exons of the CFTR gene and a
2184insA mutation in heterozygous form, respectively,
as tested by Sanger sequencing). Primer design for CFTR
mutation analysis was similar to the plasmid system’s de-
scribed above, except for the “HP in the middle” type
amplicons, which were left out of this experiment
(primers listed in Additional file 5: Table S2). Exons e3,
e14, e15, and e24 have multiple HP sections, most of
which could only be covered within the same amplicons;
therefore altogether 33 HP-containing amplicons were
tested per patient. When designing the primers, all
known single-nucleotide polymorphisms (SNPs) were
taken into consideration to maximize annealing effi-
ciency and minimize allele drop-out, which was shown
to be an issue in a previous test system [29]. We also de-
signed primers for CFTR exons that do not contain ho-
mopolymer stretches (Additional file 6: Table S3) to be
able to analyze the complete gene. The most crucial sec-
tion of the gene (within exon 14) was further tested
using 11 human DNA samples; including four wild type
and seven 2184insA heterozygotes. As with the plasmid
system, we used three additional primer pairs to gener-
ate amplicons for NGS sequencing with “proximal,”
“mid,” and “distal” HP locations. “Proximal” primers
were located at a distance of 5 and 11 base pairs from
the poly-A tract. In all samples, PicoMaxx enzyme mix
was used for the amplification processes.
All human participants gave informed consent for diag-
nostic genetic analysis. In this study DNA samples were then
applied anonymously and procedures were in accordance
with the current revision of the Helsinki Declaration. The la-
boratory is approved by the National Public Health and
Medical Officer Service (approval number: 094025024).
Sequencing data of individual reads were evaluated using
Amplicon Variant Analyzer software. We differentiated
Fig. 1 Experimental setup. In the plasmid system 4-to 6-mer homopolymers (HPs) were generated and tested using different primer sets. In the
CFTR assay, 17 samples with known genotype were tested. This test system was divided into three parts, exons containing no HPs, HP-containing
exons and the 2184 insA mutation
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between “proximal”, “mid” and “distal” type of reads refer-
ring to HP to sequencing primer distance. Statistics were
done using GraphPad Prism v5.03. Numbering of the
CFTR exons is based on current recommendations
(Ensembl ENSG00000001626). In mutation nomenclature
both Human Genome Variation Society (HGVS) and legacy
names are used, as suggested [33]. Genotyping accuracy
was defined by the percent of correct reads in samples with
known genotypes. Acceptable genotyping accuracy was de-
fined to have at least 75% accurate reads of all reads.
Results
Quality control of the template preparation
The site-directed mutagenesis experiments were con-
trolled using Sanger sequencing that were performed in
duplicates in case of all mutations. No discrepancy was
found in any of the introduced mutations (Additional
file 1: Figure S1).
Sequencing homopolymer containing plasmids
When sequencing homopolymer-containing plasmids,
mean coverage was 479 ± 145 and an evident negative cor-
relation was observed between homopolymer length and
read accuracy (Fig. 2). The average correct genotyping rate
of all four nucleotides combined was 95.8, 87.4 and 72.1%
in 4-mers, 5-mers, and 6-mers, respectively (with a 79.6–
99.3% range in 4-mers, 36.9–98.4% in 5-mers and 14.5–
93.8% in 6-mers). While the pyrosequencing-based NGS
system was able to detect poly-A 6-mers reliably (with a
mean of 76.4%), detection rates fell under 75% for poly-C,
poly-G and poly-T 6-mers (means: 71.5, 68.3 and 63.4%,
respectively). In general, longer HPs had lower genotyping
accuracy, although, the most accurate reads still reached
98.4% for 5-mers and 93.8% for 6-mers, indicating that
careful optimization in a given sequence context might
help to skip the poor performing primers and find the
most functioning ones for the analysis. After testing, pri-
mer localization failed to show any association with geno-
typing accuracy (Fig. 3).
Sequencing human DNA samples
Coding regions and exon-intron boundaries in the CFTR
gene from 6 cystic fibrosis patients with a known muta-
tion status were sequenced. Mean base coverage was 263
± 178 using our in-house assay. Altogether 246 amplicons
were included in the data analysis (> 40 reads).
Although individual read accuracy varied in a wide
range (52.2 – 99.1%), average accuracy was generally ex-
cellent using the assay (89.3%). The assay was able to de-
tect all small-scale genetic alterations (missense, nonsense,
splice site mutations, frameshift/in-frame deletions and in-
sertions) previously identified by Sanger sequencing, pro-
viding 100% sensitivity and specificity (Table 1). Regarding
the 24 HP stretches the self-designed primer set yielded
good performance with more than 80% genotyping accur-
acy in all but one HP (data not shown). The exception
was a 7A HP tract (c.2046_2052) with a 52.2% average
correctness.
Therefore a common mutation in this 7A HP
(c.2052_2053insA, a 8-mer) was further analyzed using
three primer sets (Fig. 1, primer sequences are shown in
Additional file 5: Table S2). Depending on the primer
used, correct detection of 7A in four wild type DNA
samples reached 81%, the percentage of correct reads is
shown in Fig. 4. In patients who were heterozygous for
the c.2052_2053insA mutation, we calculated the per-
centage of detected 7A and 8A signals, which, theoretic-
ally, should have been 50% for each. The detected
genotype frequencies varied in a wide range (16–49%, on
Fig. 2 Detection of homopolymers in a plasmid-based system. Read
accuracy is expressed as percentage of correct reads. (Kruskal-Wallis
test followed by Dunn’s Multiple Comparison Test, * P < 0.05 and
** P < 0.01)
Fig. 3 Sequencing primer distance has no effect on homopolymer
genotyping. Read accuracy is expressed as average percentage
of correct reads. Proximal, equal and distal localization of the
homopolymer from the sequencing primer yielded no significant
variance in read accuracy. (Kruskal-Wallis test followed by Dunn’s
Multiple Comparison Test)
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average), but the results greatly depended on the primers
used for sequence analysis. Two primer pairs (Fig. 5b
and c) proved to be rather poor performers with 45–
50% irrelevant nucleotide calls. On the other hand, se-
quencing with a third set of primers, correct 7A and
proximal 8A calls were detected with satisfactory accur-
acy (Fig. 5a), having 27% misreads on average, but even
this set could not identify 8 adenines from an approxi-
mate distance of 200 bp.
Discussion
Compared to the Sanger approach, recent next gener-
ation sequencing platforms provide deeper coverage and
unprecedented throughput. However, inherent draw-
backs in terms of read length or false calls could be an
issue in some situations [34, 35], which is why careful
correction of sequencing errors is crucial [26, 27]. Des-
pite being one of the most common NGS techniques
[36], pyrosequencing suffers from over- or undercalls in
HP runs, which was described previously [37, 38]. New
methods in processing pyrosequencing data might im-
prove the correct analysis of indel mutations even in ho-
mopolymer regions [39–41], but it is prudent to be
aware of the limitations of medical instrumentation used
for investigating patient samples.
In order to assess the accuracy of pyrosequencing in
homopolymer regions, first we established a plasmid-
based test system. The resulting plasmids contained the
most common homopolymers (i.e. 4-mer to 6-mer) as
judged by Sanger sequencing. We found that pyrose-
quencing was more reliable in the case of 4-mers and se-
quencing of longer HP tracts was increasingly less
reliable (see Fig. 2). Reliability unambiguously decreased
with the growing number of nucleotides in the homo-
polymer. Based on our previous experiences, we hypoth-
esized that in the initial phase of the sequencing
reaction (immediately following the primers) the signal-
to-noise ratio could be acceptably high for the appropri-
ate determination of subtle HP sections. Our results
using the plasmid system described was unable to
confirm our hypothesis (see Fig. 3). Despite the great
variability in sequencing accuracy, we found usable
Table 1 Performance of the assay in detecting small-scale alterations in the CFTR gene
Location cDNA position Legacy name Mutation class Sensitivity
i6 c.654-10delAGTT 786-10delAGTT Splice site 1/1
i6 c.743 + 40A > G 875 + 40A/G Splice site 1/1
i7 c.869 + 11C > T 1001 + 11C > T Splice site 1/1
e8 c.926C > G A309G Missense 1/1
e11 c.1394C > T T465I Missense 1/1
e11 c.1397C > G S466X Nonsense 1/1
e11 c.1521_1523delCTT F508del In-frame deletion* 6/6
e12 c.1624G > T G542X Nonsense* 1/1
e14 c.2012delT 2143delT Frameshift deletion 2/2
e14 c.2051_2052delAAinsG 2183AA > G Frameshift insdel* 1/1
e14 c.2052_2053insA 2184insA Frameshift insertion 6/6
e14 c.2052delA 2184delA Frameshift deletion* 1/1
e15 c.2562 T > G 2694 T/G Synonymous 4/4
i16 c.2657 + 5G > A 2789 + 5G > A Splice site* 1/1
e17 c.2856G > C M952I Missense 1/1
e21 c.3454G > C D1152H Missense* 1/1
e23 c.3846G > A W1282X Nonsense* 1/1
e27 c.4389G > A 4521G/A Synonymous 1/1
Mutations that are included in the Elucigene CF29v2 kit are labelled with an asterisk
Fig. 4 Investigating detection accuracy for 7-mers in exon 14, using
three different amplicons for sequencing. The percentage of valid
reads in 4 wild type samples is shown from both directions
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combinations of primers, for all sized homopolymers
tested, which highlights the importance of careful primer
selection and testing before being used for routine gen-
etic diagnostics.
In the second part we focused on a molecular genetic
diagnostic assay development and optimization, where
pyrosequencing of the entire coding region of the CFTR
was carried out. Here we used clinical samples that had
been tested using molecular diagnostic-level assays (a
CE-IVD kit and Sanger sequencing). The assay showed
excellent sensitivity and specificity, because all benign
and pathogenic variants (missense, nonsense, splice site
alterations, out-of-frame or in-frame deletions and inser-
tions previously identified by Sanger sequencing) were
confirmed by pyrosequencing using the in-house de-
signed primer set both in HP and non-HP containing re-
gions. Except for a unique 7A tract, sequencing of 24
HP stretches yielded good performance with genotyping
accuracy greater than 80%, including the detection of
another 7-mer (7 T) in exon 1 with 83% accuracy.
Therefore, it is likely, that homopolymer detection de-
pends not only on HP length or primer distance, but
also on several other factors, such as the nucleotide
microenvironment in the DNA sequence or the spatial
location of beads on PicoTiter plates [42].
It is extremely important to identify even small scale
insertions or deletions in homopolymer sections with
high reliability. 2184insA, a frequent CF-causing muta-
tion in Hungary and Western Ukraine [30–32] is an
eight-adenine long HP region was further analyzed by
using 11 DNA samples from CF patients. Other muta-
tions are also known (2184delA and 2183delAAinsG)
to affect the same poly-A tract, creating five or six ad-
enine long HPs. We found that mutations that lead to
the formation of 5-mers and 6-mers, can be detected
with high specificity. While genotyping of the 8-mer
c.2052_2053insA is reproducible, the detection rate
using pyrosequencing chemistry fails to reach 75%
most of the time, therefore this region of the gene still
needs to be Sanger sequenced when testing patient
samples in routine diagnostic procedures.
Conclusion
Reliable mutation detection plays a key role when using
new NGS techniques for routine clinical diagnostics. In
order to reach the required analytical sensitivity and spe-
cificity, some NGS methods might need more complex
workflow (i.e. the addition of fragment analysis or sup-
plementary Sanger sequencing of certain nucleotide re-
gions). We have developed a plasmid test system that
can be used to assess genotyping accuracy of next gener-
ation sequencing systems, which could be very useful
during the validation of those methods relative to cor-
rect homopolymer detection. Through careful planning
of PCR primers, we developed an amplicon-based NGS
assay that can be used for detection of small-scale CFTR
mutations and showed, that its analytical validity in the
clinical setting is acceptable for 4- to 6-mer HPs, but not
for 7-mers and beyond. At the same time, investigation
of the 2184insA mutation clearly shows that Sanger se-
quencing is still required in specific situations and thus,
cannot yet be eliminated from the molecular diagnostic
workflow.
Fig. 5 Investigating detection accuracy for 7- and 8-mers in exon
14 using three different amplicons for sequencing. Seven patients
heterozygous for 2184insA were analyzed, a, b and c show the
degree of deviation of the detected genotypes (7A and 8A) from
the theoretical 50%
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Additional files
Additional file 1: Figure S1. Representative Sanger electropherograms
of the generated homopolymers. 4-mers, 5-mers, and 6-mers are shown
in the left, middle, and right columns, respectively. (PDF 176 kb)
Additional file 2: Table S1. Mutagenesis, amplification and sequencing
primers in the plasmid system. Amplification/sequencing primers contain
a starting “Tag sequence,” which was separated by a space within the
primer sequence. (DOCX 35 kb)
Additional file 3: Figure S2. Representative Sanger electropherograms
of all the HP-containing exons of the CFTR gene (clinical sample number
50615). The electropherograms show the exonic sequences including
two nucleotides of the introns. (PDF 1945 kb)
Additional file 4: Figure S3. Sanger electropherogram of a sample of a
patient with a CFTR 2184insA mutation in heterozygous form. (PDF 45 kb)
Additional file 5: Table S2. Self-designed primers used for assessing HP
regions in the CFTR gene. Flopping bases on known SNPs are in brackets.
“Tag sequences” also included in the beginning of the primers, separated
by a space. (DOCX 58 kb)
Additional file 6: Table S3. Self-designed primers used for assessing
non- HP regions in the CFTR gene. “Tag sequences” also included in the
beginning of the primers, separated by a space. (DOCX 31 kb)
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